Ivosidenib (AG-120) by Nutrabiotech, potent oral IDH1 inhibitor for mutant AML and cholangiocarcinoma pharmaceutical research

Ivosidenib CAS 1448346-63-1 98% Purity Mutant IDH1 Inhibitor Powder TIBSOVO

High purity Ivosidenib powder CAS 1448346-63-1 with 98% HPLC purity. Brand name TIBSOVO, potent mutant IDH1 targeted inhibitor for AML and cholangiocarcinoma oncology research, factory bulk supply with full certificates.
Category: Tags: , , , , , , ,
Ivosidenib AG-120 (CAS 1448346-63-1) Selective Mutant IDH1 Inhibitor | AML & Cholangiocarcinoma

Ivosidenib CAS 1448346-63-1
First-in-Class Selective Mutant IDH1 Inhibitor

Ivosidenib (CAS 1448346-63-1), also AG-120, is a first-in-class, selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1). It blocks the mutant enzyme's production of the oncometabolite 2-hydroxyglutarate (2-HG), alleviating 2-HG-driven epigenetic and differentiation defects in IDH1-mutated cholangiocarcinoma, AML and glioma. Formula C28H22ClF3N6O3, MW 583.0. Research-grade with COA.

IDH1 InhibitorMutant IDH1IvosidenibAG-1202-HGCholangiocarcinomaAMLEpigenetic
Request a Quote Technical Specs
583.0
MW (C28H22ClF3N6O3)
≥98%
Purity (HPLC)
mIDH1
Oncometabolite block

Molecular Information

Name: Ivosidenib (AG-120)
CAS: 1448346-63-1
Formula: C28H22ClF3N6O3
MW: 583.0 g/mol
Class: Mutant IDH1 inhibitor
Core: Chlorophenyl pyrrolidine carboxamide
Target: Mutant IDH1 (mIDH1)
Activity: Blocks 2-HG production
MP: Not firmly reported
Appearance: White to off-white powder
Synonyms: AG-120
Storage: -20°C, protect from light
1448346-63-1
🧪
CAS Number
583.0
⚖️
Molecular Weight
Mutant IDH1 Inhibitor
🎯
Primary Activity
≥98%
✅
Purity

Product Technical Specifications

Complete physicochemical properties and QC parameters for Ivosidenib (CAS 1448346-63-1)

📋 Physicochemical Properties

  • Product NameIvosidenib (AG-120)
  • IUPAC Name(2S)-N-[1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)amino]-2-oxoethyl]-1-(4-cyano-2-pyridinyl)-N-(5-fluoro-3-pyridinyl)-5-oxopyrrolidine-2-carboxamide
  • CAS Number1448346-63-1
  • SynonymsIvosidenib; AG-120
  • Molecular FormulaC28H22ClF3N6O3
  • Molecular Weight583.0 g/mol
  • SourceSynthetic IDH1 inhibitor
  • AppearanceWhite to off-white powder
  • Water SolubilityLow
  • Organic SolubilityDMSO; some aqueous buffers
  • Compound ClassMutant IDH1 inhibitor / oncology
  • HS Code2934.99

🔬 Quality Control & Handling

  • Purity (HPLC)≥98%
  • FormCrystalline powder
  • Primary TargetMutant IDH1 (mIDH1)
  • Assay Readout2-HG levels; epigenetic marks
  • SelectivitySelective for mutant (not wild-type) IDH1
  • Storage Condition-20°C, sealed, protect from light
  • Solution StabilityDMSO stock stable weeks at -20°C
  • ShippingCold chain recommended
  • QC DocumentationCOA / HPLC / NMR / MS / MSDS
  • Pack Sizes100mg / 500mg / 1g / 5g / 10g
  • Stock StatusIn Stock
  • Use StatementResearch / investigational; not for human use

Key Molecular Targets & Pathway Nodes

Ivosidenib engages the molecular machinery and pathway nodes that define its research utility.

🧬 Mutant IDH1 🧪 2-HG (oncometabolite) 🧪 Epigenetic differentiation 🧭 Myeloid / biliary tumor cells 🧬 α-KG-dependent enzymes 🦴 Tumor growth 🔬 IDH inhibitor profiling 💧 DNA methylation 🧭 Cholangiocarcinoma 🧭 AML

How Ivosidenib Works: Cutting the 2-HG Supply Line

Ivosidenib selectively blocks mutant IDH1, lowering 2-HG and reversing epigenetic blockade

1

Selective Inhibition of Mutant IDH1

Ivosidenib is a first-in-class, selective inhibitor of the neomorphic mutant isocitrate dehydrogenase 1 (mIDH1) enzyme, with far less activity against wild-type IDH1.

2

Suppression of 2-HG Production

Mutant IDH1 aberrantly converts α-ketoglutarate to 2-hydroxyglutarate (2-HG); ivosidenib blocks this, sharply lowering intracellular 2-HG.

3

Epigenetic & Differentiation Rescue

With 2-HG reduced, α-KG-dependent DNA/histone demethylases recover, reversing aberrant gene silencing and restoring differentiation — slowing IDH1-mutant AML, cholangiocarcinoma and glioma.

⚖️ Ivosidenib vs Comparators

  • Ivosidenib (this product)Selective mutant IDH1 inhibitor
  • VorasidenibDual mIDH1/mIDH2 inhibitor
  • EnasidenibMutant IDH2 inhibitor
  • Selective EdgeMutant-IDH1-specific
  • Research NicheIDH1-mutant AML & cholangiocarcinoma

♻️ Downstream Biological Consequences

  • EnzymemIDH1 inhibited
  • Metabolite2-HG falls
  • EpigeneticsDemethylation restored
  • DifferentiationBlocked differentiation rescued
  • TumorGrowth slowed
  • BiomarkerIDH1 mutation testing

Research Applications & Models

Ivosidenib is the reference selective mutant-IDH1 inhibitor for oncology and epigenetics.

🧭

IDH1-Mutant AML Research

Foundational selective mIDH1 agent for acute myeloid leukemia models.

AML
🧭

Cholangiocarcinoma Models

Studied in IDH1-mutated biliary tract cancer.

Cholangiocarcinoma
💧

2-HG Pathway Studies

Direct measurement of oncometabolite suppression.

2-HG
🧪

Epigenetic Differentiation

Probes DNA/histone demethylase recovery.

Epigenetic
🔬

Mutant-IDH Profiling

Compared with vorasidenib/enasidenib.

Profiling
🦴

Companion-Diagnostic Research

IDH1 biomarker and resistance studies.

Biomarker

Key Literature & Landmark Publications

Landmark work on mutant IDH1 inhibitors and IDH1-mutant cancers.

Investigator reports. Ivosidenib (AG-120) selective mutant IDH1 inhibition.
Landmark reference
Clinical literature. Ivosidenib in IDH1-mutant cholangiocarcinoma.
Landmark reference
Clinical literature. Ivosidenib in IDH1-mutant AML.
Landmark reference
Review. Mutant IDH and the 2-HG oncometabolite.
Landmark reference
Structure-activity literature. Selective mIDH1 inhibitor optimization.
Landmark reference

Available Sizes & Ordering

Research-grade Ivosidenib / AG-120 (CAS 1448346-63-1) with full QC documentation; standard packs and bulk custom quantities supported.

TierPack SizeStock StatusSuitable ForLead Time
Standard100mgIn StockIDH / oncology assaysSame/next-day ship
Medium500mgIn StockCell & 2-HG studiesSame/next-day ship
Large1gIn StockIn vivo tumor modelsSame/next-day ship
Bulk5gIn StockScreening & formulationQuote to confirm
Industrial10g+Made to orderProcess developmentBatch delivery

💡 Reference sizes shown above; for exact pricing and availability please contact us for a quote. Bulk orders qualify for tiered discounts.

Frequently Asked Questions (FAQ)

What is ivosidenib and what does it inhibit?
Ivosidenib (CAS 1448346-63-1), also AG-120, is a first-in-class, selective inhibitor of mutant isocitrate dehydrogenase 1 (mIDH1) that blocks production of the oncometabolite 2-hydroxyglutarate. Formula C28H22ClF3N6O3, MW 583.0.
Which cancers is ivosidenib studied in?
IDH1-mutated acute myeloid leukemia (AML), cholangiocarcinoma (biliary tract cancer) and glioma — all driven by the mutant IDH1 / 2-HG axis.
How does it help epigenetically?
By lowering 2-HG, ivosidenib restores α-KG-dependent DNA and histone demethylases, reversing abnormal gene silencing and promoting differentiation.
What readouts confirm activity?
Measurement of 2-HG (LC-MS), mutant-IDH1 enzyme assays, and epigenetic (methylation) and differentiation markers.
How soluble is ivosidenib and how should it be prepared?
It is soluble in DMSO and some aqueous buffers; poorly in water. Prepare a DMSO stock, dilute into medium (final DMSO ≤0.1% v/v), and store at -20°C protected from light.
Is QC documentation provided?
Every batch ships with a Certificate of Analysis (COA) including HPLC purity, NMR structural confirmation and MS data; MSDS/SDS and Certificates of Origin are available on request.

Need Ivosidenib for Your Research?

Research-grade Ivosidenib (CAS 1448346-63-1) — purity ≥98% HPLC, COA included
Selective Mutant IDH1 Inhibitor — request a quote today

Request a Quote →

Related products